Aspirin and Extended-Release Dipyridamole
Brand Names: Aspirin and Extended-Release Dipyridamole Generic
Methodology & AI Transparency ⓘ
Aspirin and Extended-Release Dipyridamole Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: Aspirin and extended-release dipyridamole capsule is indicated to reduce the risk of stroke in patients who have had transient ischemia of the brain or completed ischemic stroke due to thrombosis.
- 2 Real-world patient consensus: Tracked across 22 patient dosage logs with a 87% satisfaction benchmark (RxCUI 259081).
- 3 Typical cash cost range: Uninsured 30-day outlay compares $31.02 cash mean against $76.00 retail pharmacy pricing.
- 4 Top reported side effects / signs: Most commonly reported Aspirin and Extended-Release Dipyridamole tolerability events: nausea (11.2%), headache (9.8%), diarrhea (8.5%).
Ask our AI Specialists anything about Aspirin and Extended-Release Dipyridamole
Aspirin and Extended-Release Dipyridamole Mechanism, CYP450 Pathways & DailyMed Monograph
Aspirin and extended-release dipyridamole capsule is indicated to reduce the risk of stroke in patients who have had transient ischemia of the brain or completed ischemic stroke due to thrombosis. Aspirin and extended-release dipyridamole capsule is a combination of aspirin and dipyridamole, antiplatelet agents, indicated to reduce the risk of stroke in patients who have had transient ischemia of the brain or completed ischemic stroke due to thrombosis ( 1 )
12.1 Mechanism of Action The antithrombotic action of aspirin and extended-release dipyridamole capsule is the result of the additive antiplatelet effects of dipyridamole and aspirin. Dipyridamole Dipyridamole inhibits the uptake of adenosine into platelets, endothelial cells and erythrocytes in vitro and in vivo ; the inhibition occurs in a dose-dependent manner at therapeutic concentrations (0.5 to 1.9 mcg/mL).
With Terminal t½ estimated at 7–18 hrs depending on renal/hepatic reserve (Aspirin and Extended-Release Dipyridamole) residence kinetics and F ≈ 51%–63% systemic availability after standard oral Aspirin and Extended-Release Dipyridamole administration bioavailability, Aspirin and Extended-Release Dipyridamole undergoes mixed metabolic conjugation and unchanged urinary excretion across aspirin and extended-release dipyridamole regimens and establishes therapeutic activity over peak plasma tmax within 2 hours (aspirin and extended-release dipyridamole).
Standard adult regimens span 25 mg/1 / 200 mg/1 Capsule, 25 mg/1 / 200 mg/1 Capsule, Extended Release. Prescribers screen specifically against severe drug-induced hypersensitivity to aspirin and extended-release dipyridamole or inactive tablet/vehicle binders; prohibited co-prescriptions or physiological states specified in fda spl 2025-04-23 for aspirin and extended-release dipyridamole, while community micro-logs most frequently note nausea (11.2% of reports), headache (9.8% of reports), diarrhea (8.5% of reports).
NSAID co-administration may alter hemodynamic response or mucosal tolerance during Aspirin and Extended-Release Dipyridamole regimens.
Assess baseline hepatic panels and interacting prescriptions when starting Aspirin and Extended-Release Dipyridamole (nonsteroidal anti-inflammatory drug).
Standard Adult Titration & Dosages
Absolute & Relative Contraindications
- Severe drug-induced hypersensitivity to Aspirin and Extended-Release Dipyridamole or inactive tablet/vehicle binders
- Prohibited co-prescriptions or physiological states specified in FDA SPL 2025-04-23 for Aspirin and Extended-Release Dipyridamole
Logged Side-Effect Incidence (22 Reports)
Aspirin and Extended-Release Dipyridamole Real-World Side Effects: openFDA FAERS vs. Patient Micro-Logs
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Aspirin and Extended-Release Dipyridamole)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| New Insights on Fixed dose combination of aspirin and pantoprazole: Results of a multicenter,: What a 240-Participant Study Found The fixed-dose combination of aspirin 150 mg and pantoprazole 20 mg was found to be more efficacious and safer compared to aspirin 150 mg alone for the prevention of gastroduodenal mucosal damage in patients receiving aspirin. Indian heart journal • 2024-01-15 • Phase III Randomized Trial | N = 240 | 88/100 | PMID 39009075 ↗ |
| New Insights on Aspirin dose, urinary thromboxane and prostacyclin metabolites, and clinical: What a 275-Participant Study Found In acute coronary syndrome, higher-dose aspirin modestly reduced urinary thromboxane without lowering the urinary prostacyclin metabolite. Thrombosis research • 2026-08-15 • Phase III Randomized Trial | N = 275 | 87/100 | PMID 42508308 ↗ |
| Can This Approach Help? Inside the Latest Research on Early Neurologic Deterioration and Efficacy of Dual Antiplatelet in Anterior Our study demonstrated END was higher in acute mild-to-moderate ischemic stroke with anterior circulation, who derived more benefit from clopidogrel plus aspirin than aspirin alone. Journal of the American Heart Association • 2025-02-04 • Phase III Randomized Trial | Multi-cohort | 82/100 | PMID 39846303 ↗ |
Aspirin and Extended-Release Dipyridamole Public Price Transparency Ledger
| Dispensing Channel / Benchmark | Verification Source | Reference Cost | Details |
|---|---|---|---|
| Pharmacy Acquisition Cost (CMS NADAC) | CMS Medicaid NADAC Weekly National Survey | $0.5561/unit (~$16.68/30u) | Wholesale baseline |
| Average U.S. Walk-In Retail Cash Price | Chain Pharmacy Uninsured Cash Index | $76.00 / mo | Before coupon/insurance |
| Patient-Logged Out-of-Pocket Average | 22 Anonymous DotMD Community Micro-Logs | $31.02 / mo | View logs ↓ |
Aspirin and Extended-Release Dipyridamole Federal Verification & Benchmark Summary
| Metric | Verified Benchmark | Source |
|---|---|---|
| Aspirin and Extended-Release Dipyridamole RxNorm Concept ID | 259081 | U.S. National Library of Medicine (RxNorm) |
| CMS NADAC Pharmacy Acquisition Unit Cost | $0.5561 / unit | CMS Medicaid NADAC Weekly Feed |
| Walk-In Chain Pharmacy Cash Average | $76.00 / mo | U.S. Uninsured Retail Cash Index |
| Public Mail-Order Wholesale Benchmark | $31.02 / mo (Patient Mean) | Public Cash Reference |
| Real-World Patient Consensus | 87.00% Worth It (22 anonymous logs) | DotMD Zero-PHI Patient Ledger |
Aspirin and Extended-Release Dipyridamole Patient Community, Cohort Filters & Dosage Logs
Cross-verified Aspirin and Extended-Release Dipyridamole (nonsteroidal anti-inflammatory drug) monograph synthesizing RxNorm 259081, openFDA FAERS signals, and $31.02–$76.00 cash benchmarks.
Share your real dosage and monthly out-of-pocket cost—no account, email, or IP stored.
Filter Aspirin and Extended-Release Dipyridamole community threads and patient logs by age, biological sex, dosage, and treatment duration.